

Appendix A

Claim Amendments

1. (Currently amended) ~~Calcium~~ A calcium, potassium, zinc, lithium or ~~[[and]]~~ aluminium ~~[[salts]]~~ salt of pantoprazole ~~[[and]]~~ or (S)-pantoprazole, ~~and hydrates~~ or a hydrate thereof.

2. (Currently amended) ~~Calcium~~ A calcium, potassium, zinc or ~~[[and]]~~ aluminium ~~[[salts]]~~ salt of pantoprazole ~~[[and]]~~ or (S)-pantoprazole, ~~and hydrates~~ or a hydrate thereof.

3. (Currently amended) A compound selected from the group consisting of calcium ~~Calcium~~ (S)-bis{ [5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphanyl]-1H-benzimidazolide},
zinc (S)-bis{ [5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphanyl]-1H-benzimidazolide},
aluminium (S)-tris{ [5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphanyl]-1H-benzimidazolide},
potassium (S)-{ [5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphanyl]-1H-benzimidazolide},

calcium bis{ [5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphanyl]-1H-benzimidazolide},
zinc bis{ [5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphanyl]-1H-benzimidazolide},
aluminium tris{ [5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphanyl]-1H-benzimidazolide}, [[and]]
potassium { [5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphanyl]-1H-benzimidazolide},
and the hydrates of these compounds.

4. (Currently amended) A compound selected from the group consisting of lithium ~~Lithium~~ (S)-{ [5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphanyl]-1H-benzimidazolide},

[[and]]

lithium { [5-(difluoromethoxy)]-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphanyl]-1H-benzimidazolide},
and the hydrates of these compounds.

5. (Currently amended) A pantoprazole or (S)-pantoprazole salt according to claim 1 ~~or 2 or 3 or 4~~, or a hydrate thereof, with a particle size distribution of 99 % below 100 μ m.

6. (Currently amended) ~~Medicament~~ A pharmaceutical composition comprising a compound according to claim 1, together with a pharmaceutically acceptable auxiliary any ~~of Claims 1 to 5 together with customary auxiliaries.~~

7. (Currently amended) ~~Medicament~~ A pharmaceutical composition comprising a compound according to claim 1, together with a pharmaceutically acceptable auxiliary any ~~of Claims 1 to 5 together with customary auxiliaries~~, where ~~[[the]]~~ a single dose comprises from about 10 to about 100 mg of pantoprazole or (S)-pantoprazole, ~~respectively.~~

8. - 11. (Canceled)

12. (New) A method of treating a gastrointestinal disorder in a patient comprising administering to a patient in need thereof, a compound of claim 1 or a pharmaceutically acceptable salt thereof.

13. (New) A method of treating a gastrointestinal disorder in a patient comprising administering to a patient in need thereof, a compound of claim 1 or a pharmaceutically

acceptable salt thereof, wherein said patient is a slow metabolizer.

14. (New) A method of treating a gastrointestinal disorder in a patient comprising administering to a patient in need thereof, a compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein said patient has a risk of drug interactions.

15. (New) A method of treating a gastrointestinal disorder in a patient comprising administering to a patient in need thereof, a compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein said patient needs an inhibition of acid secretion for an extended period of time.

16. (New) A pantoprazole or (S)-pantoprazole salt according to claim 2, or a hydrate thereof, with a particle size distribution of 99 % below 100 μm .

17. (New) A pantoprazole or (S)-pantoprazole salt according to claim 3, or a hydrate thereof, with a particle size distribution of 99 % below 100 μm .

18. (New) A pantoprazole or (S)-pantoprazole salt according to claim 4, or a hydrate thereof, with a particle size distribution of 99 % below 100 μm .

Appendix B

Specification Amendment

Please insert the following into the specification at
page 1, line 1:

-- This application was filed under 35 U.S.C. 371 as a
national stage of PCT/EP2005/050334, filed January 27,
2005. --

Appendix C

Abstract of the Disclosure

The invention relates to pantoprazole and (S)-pantoprazole salts and to medicaments comprising these compounds.